

4/5/1

DIALOG(R) File 351:Derwent WPI  
(c) 2004 Thomson Derwent. All rts. reserv.

003685415

WPI Acc No: 1983-45393K/ 198319

XRAM Acc No: C83-044170

**Hyperlipaemic treatment compsn. - contg. monocolin K and ML-236B  
carbonate, formed with basic macromolecular cpds. e.g. ion-exchanging  
polypeptide(s)**

Patent Assignee: ENDO A (ENDO-I)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 58055418	A	19830401				198319 B

Priority Applications (No Type Date): JP 81151620 A 19810925

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
JP 58055418	A	6		

Abstract (Basic): JP 58055418 A

Medicine (I) contains basic cpds. of monocolin K carbonate and ML-236 B carbonate formed with basic high molecule cpds. (C) having anion exchange activity. (C) are basic proteins or basic polypeptides, e.g. protamine, lysozyme, cytochrome C, trypsin, papain, ficin, polylysine, polyarginine, and polyornithine. (C) are anion exchangers possessing prim., sec., tert. and/or quat. amino functional gps.

(I) is used to prevent arteriosclerosis. (I) is administered orally and parenterally in forms of capsules, tablets and injections. Oral use is pref. Daily dose for adults is 0.5 to 1000 mg.

(I) have more efficient and stable lowering action on serum cholesterol level than monocolin K and ML-236 B. Cholesterol-lowering actions tested using rats give good results with the range between 25.8 and 39.8% at a dose of 5-20 mg/kg. Oral acute toxicity in mice is extremely low and LD50 is over 2000 mg/kg.

Title Terms: HYPERLIPAEMIA; TREAT; COMPOSITION; CONTAIN; ML; CARBONATE; FORMING; BASIC; MACROMOLECULAR; COMPOUND; ION; EXCHANGE; POLYPEPTIDE

Derwent Class: A96; B04

International Patent Class (Additional): A61K-031/19; A61K-037/08

File Segment: CPI